(Q37662200)

English

Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.

scientific article published on 24 December 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

1 reference

Europe PubMed Central

Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

0 references

Kjeld Schmiegelow

26

object named as

K Schmiegelow

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Anthony H. Goldstone

17

object named as

A H Goldstone

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Adele K Fielding

14

object named as

A K Fielding

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

author name string

M Brüggemann

1

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

A Schrauder

2

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

T Raff

3

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

H Pfeifer

4

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

M Dworzak

5

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

O G Ottmann

6

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

V Asnafi

7

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

A Baruchel

8

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

R Bassan

9

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Y Benoit

10

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

A Biondi

11

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

H Cavé

12

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

H Dombret

13

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

R Foà

15

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

N Gökbuget

16

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

N Goulden

18

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

G Henze

19

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

D Hoelzer

20

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

G E Janka-Schaub

21

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

E A Macintyre

22

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

R Pieters

23

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

A Rambaldi

24

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

J-M Ribera

25

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

O Spinelli

27

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

J Stary

28

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

A von Stackelberg

29

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

M Kneba

30

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

M Schrappe

31

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

J J M van Dongen

32

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL)

33

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

International Berlin-Frankfurt-Münster Study Group (I-BFM-SG)

34

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

publication date

24 December 2009

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

521-535

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal residula disease status as a predictor of relapse after allogenic bone marrow transplantation for children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Post-induction residual disease in translocation t(12;21)-positive childhood ALL.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal residual disease studies by flow cytometry in acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

A competitive PCR-based method using TCRD, TCRG and IGH rearrangements for rapid detection of patients with high levels of minimal residual disease in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative analysis of T-cell receptor gene rearrangements at diagnosis and relapse of T-cell acute lymphoblastic leukemia (T-ALL) shows high stability of clonal markers for monitoring of minimal residual disease and reveals the occurrence of secon

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: implications for residual disease monitoring

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Determination of minimal residual disease in leukaemia patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Harmonization of light scatter and fluorescence flow cytometry profiles obtained after staining peripheral blood leucocytes for cell surface-only versus intracellular antigens with the Fix & Perm reagent.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Generation of flow cytometry data files with a potentially infinite number of dimensions.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunophenotypic modulation in childhood precursor-B-ALL can be mimicked in vitro and is related to the induction of cell death

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Flow cytometric analysis of cerebrospinal fluid samples and its usefulness in routine clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche de

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality control of flow cytometry data analysis for evaluation of minimal residual disease in bone marrow from acute leukemia patients during treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.268

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2009.268

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37662200&oldid=2200750099"